This RA drug has the worst safety profile

Infliximab has a poorer safety profile than other targeted immunomodulators such as abatacept, adalimumab and etanercept, US researchers have found.

Their study of 10 head-to-head RCTs and 51 observational studies shows infliximab carries a higher risk of treatment discontinuations due to adverse events compared with adalimumab or etanercept in RA patients.  

In particular, infliximab has a